Online Publication of Successful Clinical Study of Nymox's AlzheimAlert Test.

Business/Medical Editors

MAYWOOD, N.J.--(BW HealthWire)--Dec. 14, 2001

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the peer-reviewed report on the successful results of a national study of its urinary AlzheimAlert(TM) test is now available online.

The article, "Clinical Study of a Urinary Competitive ELISA for Neural Thread Protein in Alzheimer Disease" is published in the January, 2002 in Neurology & Clinical Neurophysiology, the official journal of the American Academy of Clinical Neurophysiology. The article is now available on The MIT Press website at http://www-mitpress.mit.edu/e-journals/NCN/abstracts/007/ncn7-1.html.

The study reports findings that the level of the brain protein measured by AlzheimAlert(TM) (neural thread protein or NTP) increases with the severity of the disease. Patients diagnosed with early stage Alzheimer's disease had significantly lower NTP readings than patients with later stage Alzheimer's disease. The study also showed that the new AlzheimAlert(TM) test format for urine samples can accurately distinguish Alzheimer disease cases from non-Alzheimer disease cases in the clinical context. The study involved 122 cases from 102 individual physicians throughout the United States.

The article was authored by Suzanna Levy Ph.D. of Mount Sinai School of Medicine, New York; Robert Rush Ph.D. of Bio-Reference Laboratories, Inc., Elmwood Park, New Jersey; and Michael Munzar MD and Paul Averback MD of Nymox.

Michael Munzar, MD, Medical Director of Nymox said, "This study shows not only how accurate and useful a tool the AlzheimAlert(TM) urine test is for physicians in the diagnosis of Alzheimer's disease but also underlines the test's potential for monitoring disease progression and response to treatment. The correlation of NTP levels with disease stage reinforces the evidence linking overproduction of NTP in the brain to the devastating course of this deadly illness. It also supports our drug development program targeting NTP."

AlzheimAlert(TM) is Nymox's state of the art patented urine test designed to aid physicians in the diagnosis of Alzheimer's disease. AlzheimAlert(TM) is available to physicians at a cost of $295 through Nymox's certified Clinical Reference Laboratory in Maywood, New Jersey.

Nymox is working to develop treatments for Alzheimer's disease and other indications employing its proprietary drug screening platforms. One program targets NTP, the brain protein detected by AlzheimAlert(TM), and its role in the extensive brain cell loss associated with Alzheimer's disease. Another program is based on spherons, which Nymox researchers regard as a source of senile plaques, the characteristic abnormality found in abundance in the brains of patients with Alzheimer's disease and widely believed to play a major role in the cause and course of the illness. Nymox researchers believe that stopping or inhibiting the transformation of spherons into senile plaques will stop or slow the progress of this devastating illness. Nymox is also working to develop treatments for enlarged prostate (benign prostatic hyperplasia), using compounds derived from its Alzheimer's disease research. The Company is currently involved in formal preclinical studies of these treatments and plans to file an investigational new drug (IND) application with regulatory authorities in the next year. Nymox's second proprietary marketed product, NicAlert(TM), is an inexpensive, simple-to-use test strip that uses urine or saliva to determine whether a person is using tobacco products. Nymox also has several antibacterials in development, including potential treatments for E. coli 0157 food contamination, for urinary tract infections and for staph and strep infections. The Company's R&D pharmaceutical pipeline also includes candidate drugs for other indications in development.

Nymox Pharmaceutical Corporation has facilities in Maywood, NJ and Montreal. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at http://www.nymox.com.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.